Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study

BJOG. 2012 Jul;119(8):1008-13; discussion 1012-3. doi: 10.1111/j.1471-0528.2012.03359.x. Epub 2012 May 9.

Abstract

The management of anticoagulation in pregnant women with mechanical heart valves is complex. The maternal and fetal outcomes of 32 pregnancies in 15 women on three different anticoagulation regimens were compared. Anticoagulation with low-molecular-weight heparin (n=4), warfarin (n=22) and combination therapy (n=6) resulted in adverse maternal events in four (100%), three (50%) and three (14%) women, and resulted in fetal losses in one (25%), 17(77%) and three (50%) pregnancies, respectively. Whereas the rate of fetal loss in the warfarin group was high, all women in the LMWH and half of those in the combination group had serious adverse maternal events, including valve thrombosis, maternal death and postpartum haemorrhage.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects*
  • Death, Sudden / etiology
  • Drug Therapy, Combination
  • Female
  • Fetal Death / chemically induced
  • Heart Valve Prosthesis*
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Heparin, Low-Molecular-Weight / adverse effects*
  • Humans
  • Postpartum Hemorrhage / chemically induced
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Outcome
  • Retrospective Studies
  • Risk Factors
  • Thrombosis / chemically induced
  • Warfarin / administration & dosage
  • Warfarin / adverse effects*
  • Young Adult

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Warfarin